Ceftizoxime: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Ceftizoxime}} | {{Ceftizoxime}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{AK}} | ||
==Overview== | ==Overview== | ||
Revision as of 06:12, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Overview
Ceftizoxime is a third-generation cephalosporin available for parenteral administration.
Unlike other 3rd generation cephalosporins, in ceftizoxime the whole C-3 side chain has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subjected to metabolism.
Category
Cephalosporin, Third-Generation
US Brand Names
CEFIZOX®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Dosage and Administration | How Supplied
Mechanism of Action
The bactericidal action of ceftizoxime results from inhibition of cellwall synthesis. Ceftizoxime is highly resistant to a broad spectrum of betalactamases (penicillinase and cephalosporinase), including Richmond types I, II, III, TEM, and IV, produced by both aerobic and anaerobic grampositive and gramnegative organisms.[1]